| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
James O Armitage is Director at CRDF. James O Armitage's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $11K at current prices.
Net of sales, the CRDF filings show accumulation of 27,490 shares.
James O Armitage has 11 Form 4 filings on record from April 2020 to June 2026, all as Director at Cardiff Oncology (CRDF), 2020–2026.
The 11 reported transactions were 8 option or other derivative awards and 3 open-market purchases.
Counted by filing, the open-market trades come to 3 purchases worth about $79K and no sales.
The largest open-market purchase was 4,000 shares of CRDF at an average $10.82 on March 19, 2021, about $43K. Twelve months later CRDF was down 78%.